Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Insurance Coverage Requested for Candesartan as CHF Treatment
April 12, 2004
- REGULATORY NEWS IN BRIEF
April 12, 2004
- Sales of Bayer HealthCare in Japan Level Last Year: Dr Portoff
April 12, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 12, 2004
- MEDICAL DEVICE NEWS IN BRIEF
April 12, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 12, 2004
- CMIC MPSS Focusing on Subject Recruitment, Education, Training
April 12, 2004
- Sweeping Revision of OTC Drug Marketing Regulations to Be Discussed
April 12, 2004
- Companies Welcome Newcomers
April 12, 2004
- OTC NEWS IN BRRIEF
April 12, 2004
- Informed Choice Better than Informed Consent: JPMA Consumer Survey
April 12, 2004
- Japanese Healthcare Q&A (7)
April 12, 2004
- BUSINESS NEWS IN BRIEF -1-
April 12, 2004
- DIAGNOSTIC NEWS IN BRIEF
April 12, 2004
- BUSINESS NEWS IN BRIEF -2-
April 12, 2004
- WORLD NEWS IN BREIF
April 12, 2004
- Merger Synergism Boosts Chugai's Performances: Mr Nagayama
April 5, 2004
- Gastric Cancer Therapeutic GL to Be Revised
April 5, 2004
- WORLD NEWS IN BRIEF
April 5, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 5, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…